Young Patients with Hormone Receptor-Positive Breast Cancer Have a Higher Long-Term Risk of Breast Cancer Specific Death.

Jianfei FuChenhan ZhongLunpo WuDan LiTiantian XuTing JiangJiao YangJinlin Du

Published in: Journal of breast cancer (2019)

HR+ was related to LP-BCSD in the premenopausal population. LP-BCSD should be an optimal endpoint in future trials designed to evaluate the role of extended adjuvant endocrine therapy.

Keyphrases

positive breast cancer
early stage
postmenopausal women
breast cancer risk
current status
middle aged
mesenchymal stem cells
young adults
cell therapy
bone marrow
replacement therapy